Cervical Stage II Intraepithelial Neoplasia: Antivirals Efficacy
https://doi.org/10.31550/1727-2378-2022-21-1-54-58
Abstract
Study Objective: To assess the efficacy of an antiviral in the management of HPV-associated cervical stage II intraepithelial neoplasia (CIN II), using the analysis of the apoptotic marker levels and cytokine profile — caspase 3 and 9, interferon (INF) γ, interleukin (IL) 18.
Study Design: Perspective study.
Materials and Methods. We examined 126 women of reproductive age. The study included two groups: controls (40 relatively healthy fertile women without any cervical pathologies and HPV) and a group of 86 women with HPV-associated CIN II. All subjects underwent an examination; and their cytokine response and apoptotic marker level were assessed. All patients in CIN II group had the affect area excised. 43 post-excision women were followed up (sub-group A); other 43 subjects had surgery and an antiviral (sub-group B). The antiviral was administered subcutaneously once daily, 3 injections before and 3 injections after the excision. The primary efficacy criteria were absence of HPV or reduction in the viral load below significant values, and absence of pathology relapses after 6 and 12 months of the study.
Study Results. In subjects with CIN II, pre-therapy caspase 3 and 9 levels were significantly higher vs controls; INF-γ was 1.8 times higher than in controls, and mean IL-18 concentration was considerably lower (p < 0.05 in both cases). In sub-groups A and B, caspase 3 and 9 concentration in 3 and 6 months after therapy also differed significantly from controls, and in 6 months, caspase 3 and 9 concentration in sub-group В was considerably lower than in sub-group А. Women in sub-groups А and В demonstrated statistically significant difference in cytokine profile: in both sub-groups, INF-γ concentration in 10 days increased, while in 12 months it almost reached its baseline value. IL-18 in sub-group B in 10 days and 12 months was significantly higher than in sub-group А.
Conclusion. The results of the study demonstrate high HPV elimination and reduction in relapse probability after excision in patients with CIN II with the use of antivirals.
About the Authors
O. P. VinogradovaRussian Federation
8A Stasov St., Penza, 440060
N. A. Andreeva
Russian Federation
68 Bolshevistskaya Str., Saransk, 430005
O. I. Artemova
Russian Federation
40 Krasnaya St., Penza, 440026
O. V. Epifanova
Russian Federation
8A Stasov St., Penza, 440060
References
1. Shahida S.M., Lipi L.B., Rifat J.A. et al. Prevalence of cervical intraepithelial neoplasia in four Upazila of Dhaka division. Mymensingh Med. J. 2019; 28(3): 655–61.
2. Rees C.P., Brhlikova P., Pollock A.M. Will HPV vaccination prevent cervical cancer? J. R. Soc. Med. 2020; 113(2): 64–78. DOI: 10.1177/0141076819899308
3. He H., Pan Q., Pan J. et al. Study on the correlation between hTREC and HPV load and cervical CINI/II/III lesions and cervical cancer. J. Clin. Lab. Anal. 2020; 34(7): e23257. DOI: 10.1002/jcla.23257
4. Vinogradova O.P., Artemova O.I. The efficacy of human papillomavirus elimination during treatment of cervical disorders. Doctor.Ru. 2020; 19(8): 80–85. (in Russian). DOI: 10.31550/1727-2378-2020-19-8-80-85
5. Epifanova O.V., Vinogradova O.P., Andreeva N.A. Immune antiviral drug therapy in patients with HPV-associated cervical intraepithelial neoplasia grade I. Obstetrics and Gynegology. 2020; 3: 174–80. (in Russian). DOI: 10.18565/aig.2020.3.174-180
6. Sancakli Usta C., Altun E., Afsar S. et al. Overexpression of programmed cell death ligand 1 in patients with CIN and its correlation with human papillomavirus infection and CIN persistence. Infect. Agent Cancer. 2020; 15: 47. DOI: 10.1186/s13027-020-00312-9
7. Van de Laar R.L.O., Hofhuis W., Duijnhoven R.G. et al. Adjuvant VACcination against HPV in surgical treatment of Cervical Intra-epithelial Neoplasia (VACCIN study) a study protocol for a randomised controlled trial. BMC Cancer. 2020; 20(1): 539. DOI: 10.1186/s12885-020-07025-7
8. Polonskaya N.Yu., Yurasova I.V. Cytologic screening of cervical smears. Pap Test. М.: GEOTAR-Media, 2018. 168 p. (in Russian)
9. Ewaisha R., Panicker G., Maranian P. et al. Serum immune profiling for early detection of cervical disease. Theranostics. 2017; 7(16): 3814–23. DOI: 10.7150/thno.21098
10. Skare T.L., Neppel A., Machoski M.C.C. et al. Antinuclear antibodies in patients with cervical lesions and invasive cervical cancer. Immunol. Lett. 2019; 208: 8–10. DOI: 10.1016/j.imlet.2019.03.002
11. Barra F., Della Corte L., Noberasco G. et al. Advances in therapeutic vaccines for treating human papillomavirus-related cervical intraepithelial neoplasia. J. Obstet. Gynaecol. Res. 2020; 46(7): 989–1006. DOI: 10.1111/jog.14276
12. Villegas-Hinojosa E., Terán-Figueroa Y., Gallegos-García V. et al. Histopathological diagnosis of cervical biopsies: reduction of sampling errors with the evaluation of a third histologic level. Cancer Manag. Res. 2020; 12: 5099–104. DOI: 10.2147/CMAR.S225067
13. Yin G., Li J., Wu A. et al. Four categories of LEEP for CIN of various areas: a retrospective cohort study. Minim. Invasive Ther. Allied Technol. 2017; 26(2): 104–10. DOI: 10.1080/13645706.2016.1236731
14. Klügel S., Lücke C., Mehren A. et al. Patients with cervical intraepithelial neoplasms show different states of health-related quality of life and different coping styles depending on the choice of therapy: findings from the CIN study. Int. J. Womens Health. 2019; 11: 511–17. DOI: 10.2147/IJWH.S208257
15. Svidinskaya E.A., Dzhibladze T.A., Zuyev V.M. Role of determination of molecular genetic markers in the diagnosis and prediction of the course of cervix uteri diseases. Tumours of Female Reproductive System. 2010; 2: 93–8. (in Russian)
16. Trushina O.I., Novikova E.G., Shipulina O.Yu. et al. Viral load from HPV DNA as a predictive factor of malignant transformation of papilloma viral infection. In: Pokrovskiy V.I., eds. Molecular diagnosis — 2014: materials of the VIII All-Russian scientific and practical conference (with foreign participants). М.; 2014: 207. (in Russian)
Review
For citations:
Vinogradova O.P., Andreeva N.A., Artemova O.I., Epifanova O.V. Cervical Stage II Intraepithelial Neoplasia: Antivirals Efficacy. Title. 2022;21(1):54-58. (In Russ.) https://doi.org/10.31550/1727-2378-2022-21-1-54-58